Literature DB >> 11226816

Factors and strategies for improving buccal absorption of peptides.

F Veuillez1, Y N Kalia, Y Jacques, J Deshusses, P Buri.   

Abstract

Peptides and polypeptides have important pharmacological properties but only a limited number (e.g. insulin, oxytocin, vasopressin) have been exploited as therapeutics because of problems related to their delivery. The buccal mucosa offers an alternative route to conventional, parenteral administration. Peptides are generally not well absorbed through mucosae because of their molecular size, hydrophilicity and the low permeability of the membrane. Peptide transport across buccal mucosa occurs via passive diffusion and is often accompanied by varying degrees of metabolism. This review describes various approaches to improve the buccal absorption of peptides including the use of penetration enhancers to increase membrane permeability and/or the addition of enzyme inhibitors to increase their stability. Other strategies including molecular modification with bioreversible chemical groups or specific formulations such as bioadhesive delivery systems are also discussed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11226816     DOI: 10.1016/s0939-6411(00)00144-2

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  22 in total

1.  In vitro characterization of chitosan gels for buccal delivery of celecoxib: influence of a penetration enhancer.

Authors:  Yara Peluso Cid; Vinícius Pedrazzi; Valéria Pereira de Sousa; Maria Bernadete Riemma Pierre
Journal:  AAPS PharmSciTech       Date:  2011-12-09       Impact factor: 3.246

2.  Thiolated chitosans: design and in vivo evaluation of a mucoadhesive buccal peptide drug delivery system.

Authors:  Nina Langoth; Hermann Kahlbacher; Gudrun Schöffmann; Ivo Schmerold; Maximilian Schuh; Sonja Franz; Peter Kurka; Andreas Bernkop-Schnürch
Journal:  Pharm Res       Date:  2006-01-19       Impact factor: 4.200

Review 3.  Oral insulin and buccal insulin: a critical reappraisal.

Authors:  Lutz Heinemann; Yves Jacques
Journal:  J Diabetes Sci Technol       Date:  2009-05-01

4.  Efficient mucosal delivery of optical contrast agents using imidazole-modified chitosan.

Authors:  Bilal Ghosn; Anne L van de Ven; Justina Tam; Ann Gillenwater; Konstantin V Sokolov; Rebecca Richards-Kortum; Krishnendu Roy
Journal:  J Biomed Opt       Date:  2010 Jan-Feb       Impact factor: 3.170

Review 5.  Physicochemical and formulation developability assessment for therapeutic peptide delivery--a primer.

Authors:  Annette Bak; Dennis Leung; Stephanie E Barrett; Seth Forster; Ellen C Minnihan; Andrew W Leithead; James Cunningham; Nathalie Toussaint; Louis S Crocker
Journal:  AAPS J       Date:  2014-11-15       Impact factor: 4.009

Review 6.  Enhancing the buccal mucosal delivery of peptide and protein therapeutics.

Authors:  Thiago Caon; Liang Jin; Cláudia M O Simões; Raymond S Norton; Joseph A Nicolazzo
Journal:  Pharm Res       Date:  2014-08-29       Impact factor: 4.200

7.  The potential of chitosan in enhancing peptide and protein absorption across the TR146 cell culture model-an in vitro model of the buccal epithelium.

Authors:  Ana Portero; Carmen Remuñán-López; Hanne Mørck Nielsen
Journal:  Pharm Res       Date:  2002-02       Impact factor: 4.200

Review 8.  Peptidomimetic therapeutics: scientific approaches and opportunities.

Authors:  Nir Qvit; Samuel J S Rubin; Travis J Urban; Daria Mochly-Rosen; Eric R Gross
Journal:  Drug Discov Today       Date:  2016-11-14       Impact factor: 7.851

Review 9.  Oral delivery of human biopharmaceuticals, autoantigens and vaccine antigens bioencapsulated in plant cells.

Authors:  Kwang-Chul Kwon; Dheeraj Verma; Nameirakpam D Singh; Roland Herzog; Henry Daniell
Journal:  Adv Drug Deliv Rev       Date:  2012-10-23       Impact factor: 15.470

10.  Delivery of optical contrast agents using Triton-X100, part 2: enhanced mucosal permeation for the detection of cancer biomarkers.

Authors:  Anne L van de Ven; Karen Adler-Storthz; Rebecca Richards-Kortum
Journal:  J Biomed Opt       Date:  2009 Mar-Apr       Impact factor: 3.170

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.